[A Markov model to access long-term effects of rosiglitazone natrium on the treatment of type 2 diabetes].
| Autor: | Zhu CR; West China School of Public Health, Sichuan University, Chengdu 610044, China., Ni ZZ, Sun KH |
|---|---|
| Jazyk: | čínština |
| Zdroj: | Wei sheng yan jiu = Journal of hygiene research [Wei Sheng Yan Jiu] 2005 May; Vol. 34 (3), pp. 355-8. |
| Abstrakt: | Objective: The aim of this study was to estimate the long-term treatment effects of Rosiglitazone-natrium in type 2 diabetes. Methods: A Markov decision model was developed to predict, over 10 years, mortality with or without Rosiglitazone-natrium treatment. Results: During 10 years research, 14.2% patients developed to complications of type 2 diabetes mellitus, 3.8% patients should be dead in Rosiglitazone-natrium treatment group. 22.7% patients developed to complications of type 2 diabetes, 6.6% patients should be dead in non-Rosiglitazone-natrium treatment group. Conclusion: Markov decision model should be useful in accessing the long-term effects of drug treatment. Evidence on long-term benefit of Rosiglitazone-natrium could be of importance for future decision making. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|